Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.0
5.7
Journals
Pharmaceuticals
Special Issues
Pharmaceutical Blood Products
share announcement

Pharmaceutical Blood Products

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".

Deadline for manuscript submissions: 28 February 2027 | Viewed by 1896

Editors

Dr. Victor Tuan Giam Chuang

E-Mail Website
Guest Editor
Curtin Medical School, Faculty of Health Sciences, Curtin University, Kent Street, Bentley, Perth, WA 6102, Australia
Interests: albumin; liposome; drug delivery; enhanced permeability retention effect; protein; functionalization of plasma proteins for pharmaceutical applications
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Masaki Otagiri

E-Mail Website
Guest Editor
Faculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Kumamoto 860-0082, Japan
Interests: pharmacology; toxicology; pharmaceutics
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Kazuaki Taguchi

E-Mail Website
Guest Editor
Division of Pharmacodynamics, Keio University Faculty of Pharmacy, Tokyo, Japan
Interests: interdisciplinary science and engineering; nano/micro science; nanobioscience medicine; dentistry; pharmacy; drug development chemistry; medical pharmacy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pharmaceutical blood products represent a critical class of biopharmaceuticals derived from human blood or plasma, playing an indispensable role in modern medicine. These life-saving therapeutics encompass a diverse range, including plasma-derived medicinal products (e.g., immunoglobulins, albumin, and coagulation factors), recombinant blood factors, and cellular therapies. They are vital for treating a multitude of conditions, such as immunodeficiencies, bleeding disorders like hemophilia, severe burns, and various autoimmune diseases.

The field is continuously evolving, driven by advancements in fractionation technologies, viral inactivation methods, and the development of novel recombinant and gene-editing approaches that enhance safety, efficacy, and availability. Despite significant progress, challenges persist, including ensuring global supply, managing the risk of pathogen transmission, and optimizing production processes. This Special Issue aims to explore the latest advancements, innovative research, and clinical applications of pharmaceutical blood products. We invite original research articles, reviews, and short communications covering topics such as novel product development, manufacturing processes, quality control, safety profiles, clinical efficacy, and emerging therapies in this vital area of pharmaceutical science.

Dr. Victor Tuan Giam Chuang
Prof. Dr. Masaki Otagiri
Prof. Dr. Kazuaki Taguchi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmaceutical blood products
  • plasma-derived therapeutics
  • recombinant blood factors
  • cellular therapies
  • immunoglobulins
  • fractionation technologies
  • viral inactivation
  • hemophilia treatments
  • gene-editing approaches
  • clinical efficacy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 5393 KB  
Article
Intravenous Immunoglobulin Reveals a Novel Protective Mechanism: Targeting the GBP5-Driven Pyroptosis Axis in Experimental Colitis
by Qian Long, Tong Wang, Jia He, Xiaochen Yan, Zongkui Wang, Changqing Li and Rong Zhang
Pharmaceuticals 2026, 19(6), 972; https://doi.org/10.3390/ph19060972 - 22 Jun 2026
Viewed by 398
Abstract
Background: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by mucosal barrier disruption and dysregulated immune responses. While Intravenous Immunoglobulin (IVIG) is widely used for its immunomodulatory effects in various autoimmune conditions, its specific therapeutic mechanisms and molecular targets in [...] Read more.
Background: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by mucosal barrier disruption and dysregulated immune responses. While Intravenous Immunoglobulin (IVIG) is widely used for its immunomodulatory effects in various autoimmune conditions, its specific therapeutic mechanisms and molecular targets in colitis remain to be fully elucidated. Objective: To elucidate the therapeutic mechanisms of IVIG in dextran sodium sulfate (DSS)-induced colitis, with a focus on pyroptosis regulation via the NOD-like receptor (NLR) signaling pathway. Methods: Colitis was induced in mice via DSS administration. IVIG was administered intravenously during disease progression. Colon tissues underwent proteomic profiling, and key targets (GBP5, NLRP3, Pro-Caspase-1, GSDMD) were validated by Western blotting (WB), while interleukin (IL)-1β and IL-18 levels were quantified via ELISA. Results: IVIG significantly attenuated weight loss, Disease Activity Index (DAI) scores, colon shortening, and histopathological damage. Proteomics analysis identified 172 differentially expressed proteins between DSS and DSS + IVIG groups, with pronounced downregulation of GBP5 and NLR pathway components. IVIG suppressed GBP5/NLRP3/CASP1 activation, reduced GSDMD cleavage, and significantly decreased IL-1β production (while showing a decreasing trend for IL-18). Conclusions: IVIG ameliorates colitis by inhibiting the GBP5/NLRP3/CASP1-mediated pyroptosis pathway, highlighting its potential as a targeted therapy for ulcerative colitis. Full article
(This article belongs to the Special Issue Pharmaceutical Blood Products)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

22 pages, 1890 KB  
Review
When Red Blood Cells Meet Carbon Monoxide: Yin and Yang in Medicines and Pharmaceuticals
by Taisei Nagasaki, Victor Tuan Giam Chuang, Masaki Otagiri and Kazuaki Taguchi
Pharmaceuticals 2026, 19(4), 634; https://doi.org/10.3390/ph19040634 - 17 Apr 2026
Viewed by 929
Abstract
Carbon monoxide (CO) is a poisonous gas because it disrupts functional oxygen transport of red blood cell (RBC) by binding heme of hemoglobin with high affinity. Contrarily, endogenous CO, which is constantly generated in the process of heme degradation by heme oxygenase, functions [...] Read more.
Carbon monoxide (CO) is a poisonous gas because it disrupts functional oxygen transport of red blood cell (RBC) by binding heme of hemoglobin with high affinity. Contrarily, endogenous CO, which is constantly generated in the process of heme degradation by heme oxygenase, functions as a gaseous mediator necessary for maintaining physiological homeostasis. This toxicological (Yin) and physiological (Yang) duality presents a distinctive problem in medical and pharmaceutical applications, prompting the central question of this review: How can strict control over CO’s exposure dynamics, magnitude, kinetics, and tissue context be achieved to enable its safe therapeutic use? Here, we integrate the Yin and Yang of CO through an innovative exposure-engineering framework, leveraging the inherent RBC characteristics to offer a novel conceptualization for therapeutic development. We highlight the role of native RBCs as a biologically grounded platform that can convert hemoglobin binding—classically viewed as the basis of CO toxicity—into a measurable and controllable buffering mechanism. Then, reconciling the Yin and Yang of CO based on RBCs enables medical and pharmaceutical modulation that is attractive for clinical situations, therapeutics and diagnostics. Finally, we discuss key translational challenges—local concentration control, patient-specific risk stratification, manufacturability and critical quality attributes, and regulatory positioning—and outline how quantifiable exposure control can enable the safe clinical development of RBC-based CO therapy. Full article
(This article belongs to the Special Issue Pharmaceutical Blood Products)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop